Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering of 24.6 million primary shares.
Global Capital Asia reports that Celltrion Healthcare, the marketing subsidiary of Celltrion Inc, has secured approximately $886.3 million—well over a previously projected $713 million—in its July initial public offering (IPO) of 24.6 million primary shares.
CEO of Celltrion Healthcare, Kim Man-Hoon, has announced that the Korean biosimilar maker is seeking additional drug candidates as it leverages its newly raised funds to broaden its product portfolio. According to Bio Spectrum Asia, Celltrion’s expansion will include international investment, strategic acquisition, joint ventures, and licensing partnerships with new drug developers as the company expands and capitalizes on its already robust pipeline. “We have plans to launch a major biosimilar every year until 2019,” Kim said.
Kim went on to indicate that among the company’s chief aims is the acquisition of US-based biotechnology companies as Celltrion expands its presence in the lucrative US marketplace. “By taking over US biotech firms, we expect to boost Celltrion Healthcare’s brand awareness and market share,” said Kim.
The biosimilar manufacturer, which announced that it had submitted to the FDA its Biologics License Application (BLA) for a proposed biosimilar rituximab product in June, reports 6 biosimilars currently under development:
The company is also developing 5 innovator biologics for influenza, rabies, hepatitis B virus, and others.
The successful IPO is welcome news to the Incheon-based company that, earlier this year, had to delay its offering after local regulators and accountants demanded a comprehensive audit of the company’s accounting practices. In March, the Korean Institute of Certified Public Accountants, a body that reviews the eligibility of firms to offer shares, found that Celltrion Healthcare had overstated its profits by approximately $8.94 million.
While many in the industry feared that the audit would set the biosimilar manufacturer’s IPO back by 6 months or more, Celltrion Healthcare confidently—and correctly—predicted that the process would not have a significant impact on its timeline for launching the IPO.
Celltrion’s stock will begin trading on the Korean market on July 28, and is expected to be the second most valuable company on the Kosdaq index.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.